Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.

"COMPETING INTERESTS Helena Edlund, Karthick Vishwanathan, Miné de Kock, Zhongqing He, Huan Liu and Helen Tomkinson are employees of AstraZeneca. Priti Patel and Shringi Sharma are employees and stockholders of AstraZeneca. Helen Wei, Marshall Baek and Núria Buil‐Bruna are former employees of AstraZeneca. Rakesh Raman and Joseph Ware are former employees of AstraZeneca and retain AstraZeneca stock. The study was funded by Acerta Pharma, South San Francisco, CA, a member of the AstraZeneca Group."

"The authors acknowledge the Acerta Pharma study team. They also thank the patients who participated in these studies as well as their friends and family who supported them. The study was funded by Acerta Pharma, South San Francisco, CA, a member of the AstraZeneca Group. Medical writing assistance, funded by Acerta Pharma, was provided by Tracy Diaz, PhD, and Cindy Gobbel, PhD, of Peloton Advantage, LLC, an OPEN Health company."